Skip to main content
. 2020 Jan 14;4(1):181–190. doi: 10.1182/bloodadvances.2019000491

Table 1.

The association between MM genetic risk regions identified in studies of EA and MM risk in 1813 patients and 8871 controls of AA

Region SNP Position Risk allele r2 with index SNP* EA AA Power#
EUR AFR RAF† OR‡ RAF§ OR (95% CI) P PHet||
2p23.3 rs6746082** 25659244 A 0.79 1.29 0.56 1.06 (0.98-1.14) .16 .44 1.00
rs10180663†† 25633242 T 0.27 0.00 0.67 0.28 1.24 (1.14-1.36) 1.9 × 10−6 .92
2q31.1 rs4325816** 174808899 T 0.77 1.12 0.79 1.02 (0.93-1.12) .65 .22 0.70
3p22.1 rs1052501** 41925398 C 0.16 1.32 0.62 1.04 (0.96-1.13) .32 .33 1.00
rs73828280†† 41833907 T 0.88 0.44 0.17 0.45 1.09 (1.02-1.18) .02 .09
3q26.2 rs10936599** 169492101 C 0.80 1.26 0.92 1.14 (0.98-1.33) .08 .64 0.89
rs9290375†† 169566090 A 0.39 0.03 0.61 0.49 1.12 (1.03-1.20) 5.3 × 10−3 .58
5q15 rs56219066** 95242931 T 0.71 1.25 0.61 1.13 (1.05-1.22) 1.3 × 10−3 .75 1.00
5q23.2 rs6595443** 122743325 T 0.43 1.11 0.45 1.12 (1.04-1.21) 2.8 × 10−3 .61 0.81
6p22.3 rs34229995** 15244018 G 0.03 1.37 0.008
6p21.33 rs2285803** 31107258 T 0.32 1.19 0.25 1.07 (0.98-1.16) .12 .73 0.99
rs879882†† 31139452 T 0.25 0.01 0.36 0.45 1.20 (1.12-1.29) 1.0 × 10−6 .84
6q21 rs9372120** 106667535 G 0.22 1.18 0.09 1.04 (0.91-1.19) .58 .60 0.76
7p15.3 rs4487645** 21938240 C 0.65 1.38 0.89 1.38 (1.20-1.57) 3.6 × 10−6 .75 1.00
7q22.3 rs17507636** 106291118 C 0.74 1.12 0.86 1.04 (0.93-1.16) .52 .07 0.56
7q31.33 rs58618031** 124583896 T 0.72 1.12 0.79 1.07 (0.97-1.18) .16 .52 0.71
rs61068276†† 124804887 C 0.42 0.16 0.63 1.16 (1.07-1.26) 2.0 × 10−4 .57
7q36.1 rs7781265** 150950940 A 0.13 1.19 0.26 1.01 (0.92,1.11) .86 .21 0.99
rs73169662†† 150922306 C 0.91 0.00 0.09 0.03 1.32 (1.08-1.60) 5.3 × 10−3 .00
8q24.21 rs1948915** 128222421 C 0.35 1.13 0.59 1.13 (1.03-1.24) 7.2 × 10−3 .52 0.90
9p21.3 rs2811710** 21991923 C 0.66 1.15 0.36 1.15 (1.06-1.25) 1.2 × 10−3 .45 0.96
10p12.1 rs2790457** 28856819 G 0.74 1.12 0.56 1.13 (1.05-1.21) 1.9 × 10−3 .16 0.87
rs1265841†† 28920701 A 0.91 0.47 0.74 0.43 1.17 (1.08-1.26) 7.3 × 10−5 .61
16p11.2 rs13338946** 30700858 C 0.26 1.15 0.43 1.19 (1.10-1.28) 1.4 × 10−5 .28 0.97
16q23.1 rs7193541** 74664743 T 0.59 1.13 0.49 1.11 (1.03-1.19) 5.6 × 10−3 .19 0.92
17p11.2 rs4273077** 16849139 G 0.12 1.26 0.13 1.11 (0.99-1.25) .07 .90 0.99
rs34562254†† 16842991 A 0.82 0.24 0.11 0.13 1.23 (1.10-1.38) 2.1 × 10−4 .72
19p13.11 rs11086029** 16438661 T 0.24 1.14 0.19 1.08 (0.97-1.21) .17 .62 0.82
20q13.13 rs6066835** 47355009 C 0.08 1.26 0.09 0.96 (0.84-1.10) .54 .47 0.97
22q13 rs138740** 35699582 C 0.36 1.22 0.76 0.94 (0.85-1.02) .15 .76 0.99
22q13.1 rs877529** 39542292 A 0.51 1.23 0.47 1.12 (1.04-1.20) 3.4 × 10−3 .89 1.00
*

r2 was calculated among EUR/AFR populations in phase 3 1KGP.

†

RAFs were from the EUR population in phase 3 1KGP.

‡

ORs are from original GWAS reports.

§

RAFs are from AA controls.

AA MM ORs and Wald P values were adjusted for age, sex, and PCs 1-10.

||

P values of heterogeneity tests of fixed-effect meta-analyses.

#

Power was calculated using OR in the EA population, RAF in the AA population, and α = 0.05.

**

Index SNP in each risk region initially reported from GWAS studies of MM among EA populations.

††

Better AA marker in each risk region that better captured AA MM risk.